Keywords

• Afatinib
• Tovok
• Sunitinib

Quick Details

• ProName: Afatinib in stock now
• CasNo: 439081-18-2
• Molecular Formula:
• Appearance: white powder
• Application: in research
• DeliveryTime: within 3-5 days after receiving the pa...
• PackAge: Aluminum foil bag/ as requirements
• Port: China main port
• ProductionCapacity: 800 Kilogram/Month
• Purity: 99.00%
• Storage: Store in a cool dry place and keep awa...
• Transportation: by air or by sea
• LimitNum: 10 Gram

Superiority

       Inner Mongolia Yong Ming Technology Co.,Ltd--- a worthy to be depended and trusted Pharmaceutical Intermediates company. We make sure the good quality product and reasonable price. We have the good after-sales service, to solve any kinds of problems, the goal is making every customer satisfy with our company and gain the best reputation.

There are variety of products for your choose. Please contact with us at any time.

Our promise:

1. Good quality product and reasonable price~ make customers happy and save customers’ money

2. Delivery product on time~ save customers’ time

3. Professional packing~let the customers receive it successfully

4. Many payment instruments~convenient to pay 

5. Service customers forever~ to establish long-term cooperation relationship

Welcome to your inquire and suggestions, everyone here do the best for you!

Details

• Product Name: Afatinib powder
  CAS No.: 439081-18-2
  EINECS: N/A

  Molecular Weight: 485.944

  Molecular Formula: C24H25ClFN5O3
  Melting Point(°C): 213-215°C

  Specification

  Appearance	White to off-white powder	Complies
  Identification	H-NMR	Complies
  Purity(by HPLC)	Not less than 99.0%	99.47%
  Loss on dry	Not more than 0.5%	0.25%
  Single impurity	Not more than 1.0%	0.32%
  Conclusion	The batch complies with In-house standard.

   

  Afatinib (English name: Afatinib), is a kind of innovative anti-cancer targeted therapy, which is a new generation of oral targeted drugs, is the first in the world of irreversible binding to the ErbB family (including four kinds of cancer cells in different epidermal growth factor receptor, such as EGFR, HER2, ErbB3 and ErbB4) anticancer standard the target drug, and more effectively and to block the growth of cancer cells caused by signal, reduce or delay the proliferation of cancer cells.

   

  Afatinib has been in the United States, Europe and Taiwan approved national area used as first-line therapy, has been applied to the epidermal growth factor receptor (English: EGFR) mutations of non-small cell lung cancer cancer cells (English: NSCLC) is a daily oral treatment, the targeted therapy drug。

   

Welcome to your inquire, thanks in  advance.

More information: mona@nmg-ym.com

Skype: live:mona_3363